N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy

[1] Feigin VL(2016)Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet Neurol 15 913-924

[2] Roth GA(2016)Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically Ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban) Circulation 10 667-684

[3] Naghavi M(2017)The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis Expert Rev Hematol 339 321-328

[4] Parmar P(1998)Natriuretic peptides New Engl J Med 50 2357-2368

[5] Krishnamurthi R(2007)Natriuretic peptides J Am Coll Cardiol 350 655-663

[6] Chugh S(2004)Plasma natriuretic peptide levels and the risk of cardiovascular events and death New Engl J Med 293 1609-1616

[7] Mensah GA(2005)N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 45 1646-1650

[8] Norrving B(2014)N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort Stroke 125 1605-1616

[9] Shiue I(2012)Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy Circulation 61 2274-2284

[10] Ng M(2013)N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation) J Am Coll Cardiol 375 534-544

[1] Feigin VL(2016)Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet Neurol 15 913-924

[2] Roth GA(2016)Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically Ill patients: an APEX trial substudy (acute medically ill venous thromboembolism prevention with extended duration betrixaban) Circulation 10 667-684

[3] Naghavi M(2017)The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis Expert Rev Hematol 339 321-328

[4] Parmar P(1998)Natriuretic peptides New Engl J Med 50 2357-2368

[5] Krishnamurthi R(2007)Natriuretic peptides J Am Coll Cardiol 350 655-663

[6] Chugh S(2004)Plasma natriuretic peptide levels and the risk of cardiovascular events and death New Engl J Med 293 1609-1616

[7] Mensah GA(2005)N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 45 1646-1650

[8] Norrving B(2014)N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort Stroke 125 1605-1616

[9] Shiue I(2012)Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy Circulation 61 2274-2284

[10] Ng M(2013)N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation) J Am Coll Cardiol 375 534-544